Imaging tumor response following liver-directed intra-arterial therapy

Abdominal Imaging

Volumn 38, Issue 6, 2013, Pages 1286-1299

  Guo, Yang ^a   Yaghmai, Vahid ^a   Salem, Riad ^a   Lewandowski, Robert J ^a   Nikolaidis, Paul ^a   Larson, Andrew C ^a,b   Miller, Frank H ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Northwestern University   (United States)

Author keywords

Chemoembolization; DW MRI; Hepatic malignancy; Hepatocellular carcinoma; Liver metastases; PET; RECIST; Yttrium radioembolization

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; ARTIFICIAL EMBOLISM; CHEMOEMBOLIZATION; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HUMAN; LIVER CANCER; LIVER METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOEMBOLIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSARTERIAL EMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME;

CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DIAGNOSTIC IMAGING; EMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84890121073     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-013-0017-5     Document Type: Article

References (92)

1. Salem R, Lewandowski RJ (2013) Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2012.12.039
2. Lewandowski RJ, Geschwind JF, Liapi E, Salem R (2011) Transcatheter intraarterial therapies: rationale and overview. Radiology 259(3):641-657. doi: 10.1148/radiol.11081489
3. Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver metastases. Radiology 266(2):407-430. doi: 10.1148/radiol.12112544
4. Bower M, Metzger T, Robbins K, et al. (2010) Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB 12(1):31-36. doi: 10.1111/j.1477-2574.2009.00117.x
5. Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572-586. doi: 10.1002/jso.20609
6. Solomon B, Soulen MC, Baum RA, et al. (1999) Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 10(6):793-798
7. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429-442. doi: 10.1053/jhep.2003.50047
8. Carter S, Martin Ii RC (2009) Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB 11(7):541-550. doi: 10.1111/j.1477-2574. 2009.00071.x
9. Poon RT, Tso WK, Pang RW, et al. (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5(9):1100-1108. doi: 10.1016/j.cgh.2007.04.021
10. Memon K, Lewandowski RJ, Riaz A, Salem R (2013) Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res 190:207-224. doi: 10.1007/978-3-642-16037-0-14
11. Gillmore R, Stuart S, Kirkwood A, et al. (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55(6):1309-1316. doi: 10.1016/j.jhep.2011.03.007
12. Kanematsu M, Goshima S, Watanabe H, et al. (2012) Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci 11(3):151-161
13. Ng CS, Chandler AG, Wei W, et al. (2011) Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 260(3):762-770. doi: 10.1148/radiol.11110331
14. Haider MA, Farhadi FA, Milot L (2010) Hepatic perfusion imaging: concepts and application. Magn Reson Imaging Clin N Am 18(3):465-475, x. doi: 10.1016/j.mric.2010.07.009
15. WHO (1979) WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization Offset Publication
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026
18. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-1236. doi: 10.1002/hep.20933
19. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-430
20. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60. doi: 10.1055/s-0030- 1247132
21. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S. doi: 10.2967/jnumed.108.057307
22. Choi H, Charnsangavej C, Faria SC, et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753-1759. doi: 10.1200/JCO.2006.07.3049
23. Kudo M, Kubo S, Takayasu K, et al. (2010) Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 40(7):686-692. doi: 10.1111/j.1872-034X. 2010.00674.x
24. Mazumdar M, Smith A, Schwartz LH (2004) A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 57(4):358-365. doi: 10.1016/j.jclinepi.2003.07.015
25. Suzuki C, Jacobsson H, Hatschek T, et al. (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28(2):329-344. doi: 10.1148/rg.282075068
26. Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24(20):3245-3251. doi: 10.1200/JCO.2006.06.5599
27. Forner A, Ayuso C, Varela M, et al. (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115(3):616-623. doi: 10.1002/cncr.24050
28. Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390. doi: 10.1056/ NEJMoa0708857
29. Llovet JM, Di Bisceglie AM, Bruix J, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698-711. doi: 10.1093/jnci/djn134
30. Prajapati HJ, Spivey JR, Hanish SI, et al. (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24(4):965-973. doi: 10.1093/annonc/mds605
31. Duke E, Deng J, Ibrahim SM, et al. (2010) Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 21(4):515-521. doi: 10.1016/j.jvir.2009. 11.020
32. Memon K, Kulik L, Lewandowski RJ, et al. (2011) Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141(2):526-535, e521-522. doi: 10.1053/j.gastro.2011.04. 054
33. Riaz A, Miller FH, Kulik LM, et al. (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. J Am Med Assoc 303(11):1062-1069. doi: 10.1001/jama.2010.262
34. Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 188(3):768-775. doi: 10.2214/AJR.06.0706
35. Welsh JS (2007) Radiographically identified necrosis after 90Y microsphere brachytherapy: a new standard for oncologic response assessment? AJR Am J Roentgenol 188(3):765-767. doi: 10.2214/AJR.07.5320
36. Shaheen M, Hassanain M, Aljiffry M, et al. (2012) Predictors of response to radio-embolization (TheraSphere(R)) treatment of neuroendocrine liver metastasis. HPB 14(1):60-66. doi: 10.1111/j.1477-2574.2011.00405.x
37. Bargellini I, Bozzi E, Campani D, et al. (2013) Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 82(5):e212-e218. doi: 10.1016/j.ejrad.2012.12.009
38. Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185-1193. doi: 10.1002/hep.22747
39. Newatia A, Khatri G, Friedman B, Hines J (2007) Subtraction imaging: applications for nonvascular abdominal MRI. AJR Am J Roentgenol 188(4):1018-1025. doi: 10.2214/AJR.05.2182
40. Winters SD, Jackson S, Armstrong GA, et al. (2012) Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. Clin Radiol 67(7):649-655. doi: 10.1016/j.crad.2011.11.013
41. Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348-355. doi: 10.1002/jmri.22038
42. Lin M, Pellerin O, Bhagat N, et al. (2012) Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol 23(12):1629-1637. doi: 10.1016/j.jvir.2012.08.028
43. Galizia MS, Tore HG, Chalian H, et al. (2012) MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. Acad Radiol 19(1):48-54. doi: 10.1016/j.acra.2011.09.005
44. Benjamin RS, Choi H, Macapinlac HA, et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-1764. doi: 10.1200/JCO.2006.07.3411
45. Tochetto SM, Rezai P, Rezvani M, et al. (2010) Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET? Radiology 255(1):164-172. doi: 10.1148/radiol.09091028
46. Tochetto SM, Tore HG, Chalian H, Yaghmai V (2012) Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. AJR Am J Roentgenol 198(5):1093-1099. doi: 10.2214/AJR.11.6622
47. Song do S, Choi JY, Yoo SH, et al. (2013) DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarterial chemoembolization: a pilot study. Gut Liver 7(1):89-95. doi: 10.5009/gnl.2013.7.1.89
48. Malayeri AA, El Khouli RH, Zaheer A, et al. (2011) Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics 31(6):1773-1791. doi: 10.1148/rg.316115515
49. Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11(1):92-102. doi: 10.1016/S1470-2045(09)70190-1
50. Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254(1):47-66. doi: 10.1148/radiol.09090021
51. Qayyum A (2009) Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 29(6):1797-1810. doi: 10.1148/rg.296095521
52. Geschwind JF, Artemov D, Abraham S, et al. (2000) Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11(10):1245-1255
53. Yuan YH, Xiao EH, Liu JB, et al. (2007) Characteristics and pathological mechanism on magnetic resonance diffusion-weighted imaging after chemoembolization in rabbit liver VX-2 tumor model. World J Gastroenterol 13(43):5699-5706
54. Deng J, Virmani S, Young J, et al. (2008) Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging 27(5):1069-1076. doi: 10.1002/jmri.21327
55. Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181(3):708-710. doi: 10.2214/ajr.181.3.1810708
56. Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M (1997) Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 204(3):739-744
57. Taouli B, Vilgrain V, Dumont E, et al. (2003) Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226(1):71-78
58. Kamel IR, Bluemke DA, Eng J, et al. (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17(3):505-512. doi: 10.1097/01.RVI.0000200052.02183.92
59. Chen CY, Li CW, Kuo YT, et al. (2006) Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience. Radiology 239(2):448-456. doi: 10.1148/radiol.2392042202
60. Chung JC, Naik NK, Lewandowski RJ, et al. (2010) Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 16(25):3161-3167
61. Dong S, Ye XD, Yuan Z, Xu LC, Xiao XS (2012) Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization. Eur J Radiol 81(3):472-477. doi: 10.1016/j.ejrad.2010.12.081
62. Buijs M, Kamel IR, Vossen JA, et al. (2007) Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 18(8):957-963. doi: 10.1016/j.jvir.2007.04.025
63. Liapi E, Geschwind JF, Vossen JA, et al. (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 190(1):67-73. doi: 10.2214/ajr.190.4-supplement.0a67
64. Vossen JA, Kamel IR, Buijs M, et al. (2008) Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr 32(3):347-352. doi: 10.1097/RCT.0b013e318134ecd6
65. Bonekamp S, Shen J, Salibi N, et al. (2011) Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 35(2):167-173. doi: 10.1097/RCT.0b013e3182004bfb
66. Bonekamp S, Jolepalem P, Lazo M, et al. (2011) Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 260(3):752-761. doi: 10.1148/radiol.11102330
67. Li Z, Bonekamp S, Halappa VG, et al. (2012) Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 264(1):97-109. doi: 10.1148/radiol.12112161
68. Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264(1):285-294. doi: 10.1148/radiol.12112142
69. Kubota K, Yamanishi T, Itoh S, et al. (2010) Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncol Rep 24(3):727-732
70. Goshima S, Kanematsu M, Kondo H, et al. (2008) Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27(4):834-839. doi: 10.1002/jmri.21316
71. Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193(4):1044-1052. doi: 10.2214/AJR.08.1461
72. Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B (2013) Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol 82(4):577-582. doi: 10.1016/j.ejrad.2012.11.026
73. Venturini M, Pilla L, Agostini G, et al. (2012) Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients. J Vasc Interv Radiol 23(7):937-941. doi: 10.1016/j.jvir.2012.04.027
74. Yuan Z, Ye XD, Dong S, et al. (2010) Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 75(1):e9-14. doi: 10.1016/j.ejrad.2009. 05.040
75. Sahin H, Harman M, Cinar C, et al. (2012) Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging. J Vasc Interv Radiol 23(2):241-247. doi: 10.1016/j.jvir.2011.08.030
76. Deng J, Miller FH, Rhee TK, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17(7):1195-1200. doi: 10.1097/01.RVI.0000227234.81718.EB
77. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF (2007) Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18(1 Pt 1):49-56. doi: 10.1016/j.jvir.2006.10.005
78. Rhee TK, Naik NK, Deng J, et al. (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19(8):1180-1186. doi: 10.1016/j.jvir.2008.05.002
79. Bonekamp S, Halappa VG, Geschwind JF, et al. (2013) Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. doi: 10.1148/radiol.13121637
80. Shankar LK, Hoffman JM, Bacharach S, et al. (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47(6):1059-1066
81. Miller FH, Keppke AL, Reddy D, et al. (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 188(3):776-783. doi: 10.2214/AJR.06.0707
82. Weber WA (2006) Positron emission tomography as an imaging biomarker. J Clin Oncol 24(20):3282-3292. doi: 10.1200/JCO.2006.06.6068
83. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW (1996) Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 78(10):2216-2222
84. Bienert M, McCook B, Carr BI, et al. (2005) 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 32(7):778-787. doi: 10.1007/s00259-004-1752-1
85. Wong CY, Qing F, Savin M, et al. (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101-1106. doi: 10.1097/01.RVI.0000168104.32849.07
86. Lewandowski RJ, Thurston KG, Goin JE, et al. (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16(12):1641-1651. doi: 10.1097/01.RVI.0000179815. 44868.66
87. Gates VL, Esmail AA, Marshall K, Spies S, Salem R (2011) Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med 52(1):72-76. doi: 10.2967/jnumed.110.080986
88. Haug AR, Heinemann V, Bruns CJ, et al. (2011) 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 38(6):1037-1045. doi: 10.1007/s00259-011-1736-x
89. Haug AR, Tiega Donfack BP, Trumm C, et al. (2012) 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 53(3):371-377. doi: 10.2967/jnumed.111.096230
90. Zerizer I, Al-Nahhas A, Towey D, et al. (2012) The role of early (1)(8)F-FDG PET/CT in prediction of progression-free survival after (9)(0)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 39(9):1391-1399. doi: 10.1007/s00259-012-2149-1
91. Young H, Baum R, Cremerius U, et al. (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773-1782
92. Reyes DK, Vossen JA, Kamel IR, et al. (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15(6):526-532. doi: 10.1097/PPO.0b013e3181c5214b